Literature DB >> 7021571

Neutralization of adenovirus infectivity and cytotoxin in various cell cultures.

E Schrader, R Wigand.   

Abstract

The neutralization of human adenovirus 5 and 11 by homologous and heterologous rabbit antisera was determined by CPE inhibition in various cell cultures (HeLa, HEL, Vero, secondary kidney cells from cercopithecus, rabbit, mouse), or in HeLa cells made impermissive by IUdR inhibition. The results concerning sensitivity and specificity were similar in all cases. Crude and purified virus showed similar neutralization. Immunofluorescence neutralization in HeLa cell cultures gave similar results; this method is suitable for demonstrating subtle immunological relations between adenovirus types. The neutralization of the early cytopathic factor ('cytotoxin') showed a pattern of cross-reactivity different from the virion; the cytotoxin was found to be active in part of the cell cultures only. It is concluded from the results that the virus function(s) blocked by antibody appear to be identical for the replicative cycle in infection and for the initiation of the abortive infection in non-permissive cells. Hence, either kind of cells may be used for neutralization tests.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7021571     DOI: 10.1016/0166-0934(81)90055-0

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  8 in total

1.  Phylogenetic analysis and structural predictions of human adenovirus penton proteins as a basis for tissue-specific adenovirus vector design.

Authors:  Ijad Madisch; Soeren Hofmayer; Christian Moritz; Alexander Grintzalis; Jens Hainmueller; Patricia Pring-Akerblom; Albert Heim
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

2.  Investigation of an outbreak of adenovirus type 3 infection in a boys' boarding school.

Authors:  S B Payne; E A Grilli; A J Smith; T W Hoskins
Journal:  J Hyg (Lond)       Date:  1984-10

3.  Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively.

Authors:  J C De Jong; A G Wermenbol; M W Verweij-Uijterwaal; K W Slaterus; P Wertheim-Van Dillen; G J Van Doornum; S H Khoo; J C Hierholzer
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

4.  Complete genome analysis of a novel intertypic recombinant human adenovirus causing epidemic keratoconjunctivitis in Japan.

Authors:  Hisatoshi Kaneko; Koki Aoki; Shigeaki Ohno; Hiroaki Ishiko; Tsuguto Fujimoto; Masayuki Kikuchi; Seiya Harada; Gabriel Gonzalez; Kanako O Koyanagi; Hidemi Watanabe; Tatsuo Suzutani
Journal:  J Clin Microbiol       Date:  2010-12-08       Impact factor: 5.948

5.  Novel human adenovirus causing nosocomial epidemic keratoconjunctivitis.

Authors:  Hiroaki Ishiko; Yasushi Shimada; Tsunetada Konno; Akio Hayashi; Takeshi Ohguchi; Yoshitsugu Tagawa; Koki Aoki; Shigeaki Ohno; Shudo Yamazaki
Journal:  J Clin Microbiol       Date:  2008-04-02       Impact factor: 5.948

6.  Epidemic keratoconjunctivitis due to the novel hexon-chimeric-intermediate 22,37/H8 human adenovirus.

Authors:  Koki Aoki; Hiroaki Ishiko; Tsunetada Konno; Yasushi Shimada; Akio Hayashi; Hisatoshi Kaneko; Takeshi Ohguchi; Yoshitsugu Tagawa; Shigeaki Ohno; Shudo Yamazaki
Journal:  J Clin Microbiol       Date:  2008-08-13       Impact factor: 5.948

7.  Effective Apical Infection of Differentiated Human Bronchial Epithelial Cells and Induction of Proinflammatory Chemokines by the Highly Pneumotropic Human Adenovirus Type 14p1.

Authors:  Elena Lam; Mirja Ramke; Gregor Warnecke; Sonja Schrepfer; Verena Kopfnagel; Thomas Dobner; Albert Heim
Journal:  PLoS One       Date:  2015-07-13       Impact factor: 3.240

8.  Impaired neutralising antibody formation and high transduction efficacy after isolated hepatic perfusion with adenoviral vectors.

Authors:  B van Etten; A M M Eggermont; G Ambagtsheer; S T van Tiel; T L M ten Hagen
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.